Atherosclerosis and Hyperlipidemia

ACC.24: Olezarsen for Hypertriglyceridemia and ASCVD

Brian Bergmark,

Watch time: 3m 40s
ACC.24: The LIBerate-CVD Trial

Evan A Stein,

Watch time: 7m 18s

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 1h 35m 42s (16 videos)
ESC 23: LIBerate-HeFH Study

Frederick Raal,

Watch time: 4m 16s
ESC 23: OCEAN(a)-DOSE Trial Update

Michelle O'Donoghue,

Watch time: 3m 22s

Joost Daemen, Allen Jeremias, Ziad A Ali, et al

Watch time: 55m 46s (1 video)

Lale Tokgözoğlu, Kausik Ray, Ulrich Laufs, et al

Watch time: 1h 23m 3s (5 videos)

Julia Brandts,

Watch time: 1m 43s

Julia Brandts,

Watch time: 1m 44s

Marinela Beznă , Gabriela Mitoaica , Lorena Ungureanu , et al

Read time: 1 Min
Dietary Sodium Intake and Atherosclerosis

Jonas Wuopio,

Watch time: 3m 1s

Breda Hennessey , Asad Shabbir , Alejandro Travieso , et al

Read time: 23 Mins

Jean-Claude Tardif,

Watch time: 1h 4m 5s (13 videos)

Heather Currie , Christine Williams ,

Read time: 10m

Edward T Carreras , Donna M Polk ,

Hans-Willi Breuer ,

FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s

Lale Tokgözoğlu, Kausik Ray, Ulrich Laufs, et al

Watch time: 1h 23m 3s (5 videos)
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s

Ewa Dembowski , Michael H Davidson ,

Sergio Fazio ,

Sumanth Khadke , Jovana Vidovic , Vinod Patel ,

Alberto Lorenzatti , Peter P Toth ,

Ahmet Fuat, Jim Moore, Gary Ford, et al

Watch time: 1h 35m (4 videos)

Media

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 1h 35m 42s (16 videos)

Joost Daemen, Allen Jeremias, Ziad A Ali, et al

Watch time: 55m 46s (1 video)

Lale Tokgözoğlu, Kausik Ray, Ulrich Laufs, et al

Watch time: 1h 23m 3s (5 videos)
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study

Annapoorna Kini ,

Watch time: 8m 1s
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen,

Watch time: 16m 12s
View from the Thoraxcenter: What's Hot at ACC.23?

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 22m 4s

Ahmet Fuat, Gary Ford, Kausik Ray, et al

Watch time: 1h 36m 11s
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue,

Watch time: 14m 28s
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 20s
FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s
FOURIER-OLE: The Trial in Context

Marc S Sabatine,

Watch time: 3m 24s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s

Media

ACC.24: The LIBerate-CVD Trial

Evan A Stein,

Watch time: 7m 18s
ACC.24: Olezarsen for Hypertriglyceridemia and ASCVD

Brian Bergmark,

Watch time: 3m 40s

Joost Daemen, Allen Jeremias, Ziad A Ali, et al

Watch time: 55m 46s (1 video)
ACC 2020: Inclisiran Potently and Durably Reduces Ldl-c

R Scott Wright,

Watch time: 13m 43s

Nina Barnett, Yassir Javaid, Paresh Parmar, et al

Watch time: 18m 47s (4 videos)
ACC 23: MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients

Christie Ballantyne,

Watch time: 3m 44s
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study

Annapoorna Kini ,

Watch time: 8m 1s
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen,

Watch time: 16m 12s

Julia Brandts,

Watch time: 1m 43s

Julia Brandts,

Watch time: 1m 44s

Lale Tokgözoğlu, Kausik Ray, Ulrich Laufs, et al

Watch time: 1h 23m 3s (5 videos)
ESC 23: OCEAN(a)-DOSE Trial Update

Michelle O'Donoghue,

Watch time: 3m 22s

Articles

Novel Treatments for Cardiovascular Disease

Leo Buckley

,

Ahmed Aldemerdash

,

Citation:

US Cardiology Review 2017;11(2):98–104.

DOI:

https://doi.org/10.15420/usc.2017:20:2
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 2155
  • Downloads: Downloads 10

Inflammation Revisited: Atherosclerosis in The Post-CANTOS Era

Wolfgang Koenig

,

Citation:

European Cardiology Review 2017;12(2):89–91

DOI:

https://doi.org/10.15420/ecr.2017:18:1
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 672
  • Downloads: Downloads 5
  • Citations: 18

Cardiovascular Risk Management Targeting Inflammation in Addition to Lipid-lowering Therapy

Koji Hasegawa

,

Citation:

European Cardiology Review 2017;12(2):88

DOI:

https://doi.org/10.15420/ecr.2017:25:1
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 518
  • Downloads: Downloads 6

Effects of Pharmacotherapy for Smoking Cessation on LOX Index, a Cardiovascular Risk Marker

Maki Komiyama

,

Hiromichi Wada

,

Hajime Yamakage

,

Noriko Asahara

,

Sayaka Shimada

,

Masaharu Akao

,

Tatsuya Morimoto

,

Yuko Takahashi

,

Tatsuya Sawamura

,

Koji Hasegawa

,

Citation:

European Cardiology Review 2017;12(2):96.

DOI:

https://doi.org/10.15420/ecr.2017:23:5
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 316
  • Downloads: Downloads 2